Drug intelligence / Profile preview

ENA-002

Development stage: Preclinical
Lead developer: Enalare Therapeutics
Modality: Small Molecules

Overview

ENA-002 is a preclinical-stage small molecule being developed by Enalare Therapeutics. It acts as a modulator of potassium (K+) channels, specifically designed to influence respiratory physiology. The drug is being investigated for the treatment of various respiratory conditions, including sleep apnea, chronic obstructive pulmonary disease (COPD), and altitude sickness, as well as orphan diseases associated with potassium channel dysfunction. By modulating these channels, ENA-002 aims to improve ventilatory control and respiratory stability in patients with compromised breathing.

Targets

KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)

Beyond the preview

Go deeper on ENA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENA-002.

Explore the full profile